Ribozymes are catalytic RNA that bind and cleave specific regions of target RNA. Therefore, protein synthesis by the target RNA may be specifically inhibited by ribozymes. In this study, we have investigated if ribozymes possess therapeutic activity on inflammatory processes in vivo, as judged from effects on an arthritis model. A hammerhead ribozyme against TNF-a was designed and its catalytic activity in vitro was verified. The ribozyme was employed in vivo without any delivery system, as the plasmid-based ribozyme was taken up adequately by various tissues in mice by intravenous injection. The ability of the ribozyme to regulate the development of collagen-induced arthritis (CIA), a model largely dependent on TNF-a, was investigated. Systemic administration of the ribozyme to mice immunized with collagen type II in CFA significantly reduced the development of CIA. No effect was observed with a catalytically inactive variant of the ribozyme. Furthermore, the ribozyme efficiently blocked cartilage and bone destruction in the joints and ameliorated established CIA. These data demonstrate for the first time that gene targeting by a ribozyme to inactivate TNF-a in vivo is highly efficient in suppressing autoimmune arthritis, thus providing proof of concept that it may be used as therapeutic tool for TNF-a-dependent chronic inflammatory disorders.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease, characterized by chronic inflammation in the joints and subsequent destruction of the cartilage and bone. The etiology of RA is still unknown, but it has been recognized that many cytokines are upregulated in RA synovium, 1,2 which correlates with the joint lesions. 3, 4 In particular, TNF-a has been identified in the pathogenesis of RA not only for its ability to induce directly cartilage and bone degradation 5, 6 but also for its capacity to initiate an inflammatory response. Thus, TNF-a promotes secretion of other inflammatory mediators, such as IL-1, IL-6 and GM-CSF. [7] [8] [9] [10] Further, mice expressing human TNF-a transgenes develop chronic, progressive polyarthritis and treatment with anti-TNF-a antibodies inhibits this disease as well as collagen-induced arthritis (CIA), a murine model of RA. [11] [12] [13] [14] Altogether, these findings have contributed to the emerging concept that TNF-a is a good therapeutic target in RA. Accordingly, therapies with monoclonal antibodies or soluble receptors to TNF-a show significant clinical benefits in RA. [15] [16] [17] [18] [19] Although they demonstrate clinical efficacy, these agents have certain disadvantages, such as the need for repeated high doses and the potential of inducing allergic reactions or immune responses to the proteinbased drug. A possible alternative may be to inhibit TNF-a production at the post-transcriptional level. Inhibition of TNF-a mRNA production may be a more efficient method of treating conditions associated with overexpression of the protein. One approach by which to block gene expression is through the use of ribozymes. Ribozymes are catalytic RNA molecules that cleave specific target RNA. [20] [21] [22] They function by binding with the target RNA through Watson-Crick base pairing and inactivate it by cleaving the phosphodiester backbone. Development of this ribozyme strategy has been successful in inhibiting gene expression in cell cultures. [22] [23] [24] [25] Ribozyme-mediated therapy has also been beneficial in RA research, inhibiting different genes in synovial cells. [26] [27] [28] [29] [30] However, there is a need to explore the efficacy of in vivo ribozyme treatment in RA models. Here, for the first time, we have investigated the therapeutic activity of a ribozyme in a model of autoimmune arthritis. We designed a hammerhead ribozyme against murine TNFa (mTNF-a) that could specifically cleave TNF-a. The therapeutic potential of the ribozyme in vivo was tested by systemic delivery of plasmid DNA to mice immunized for CIA. We report here that the TNF-a targeting ribozyme has substantial therapeutic efficacy on autoimmune arthritis, thus indicating its potential clinical use to control TNF-a-dependent chronic inflammatory conditions of autoimmune origin.
Results

Design and cleavage activity of ribozyme against TNF-a
In order to design a ribozyme to cleave TNF-a mRNA, we first had to predict the secondary structure of mTNF-a mRNA to identify an accessible target site for the ribozyme. This was carried out through energy minimization using the computational program, MFOLD and FOLDRNA, based on Zuker's algorithm. 31 We found an accessible GUC target site at the 666 nucleotide (nt) position and selected the sequence stretch of 20 nt surrounding this site. The site was scanned using BLAST (Basic Local Alignment Search Tool) to eliminate potential targets with substantial homology to other non-TNFa mRNA. The resulting ribozyme was denoted Rz666 (Figure 1a ) and corresponding oligonucleotides were annealed and cloned in the pStuI and pCI-neo vectors. Similarly, a mutant variant of Rz666 was constructed, with a single base pair substitution within its catalytic core, making it catalytically inactive.
To test the catalytic activity and specificity of the ribozyme, we performed an in vitro cleavage reaction with in vitro run off transcription-synthesized Rz666 and mTNF-a mRNA. Target RNA was cleaved at the specific position, generating two cleavage products of expected sizes (344 and 203 nt) (Figure 1b) . In contrast, the mutant form of Rz666 had no detectable cleavage activity. Increasing the molar ratio of Rz666 to target augmented the cleavage products ( Figure 1c ).
Expression of Rz666 following systemic delivery in vivo
The uptake of the ribozyme following in vivo transfection with the plasmid was investigated. Mice were given one intravenous (i.v.) injection of Rz666 in PBS and were killed 24 h, 7 days or 14 days after ribozyme administration. pCI-neoRz666 expression was quantified by realtime PCR in the synovium, liver, spleen, kidney and heart. Results showed that a single injection induced Rz666 expression in all analyzed tissues, with the highest expression in the liver and spleen (Figure 2a ). Transgene expression was also found in the heart, kidney and synovium, at levels about 100-fold lower than in the liver. Maximum expression was seen in the majority of the tissues 24 h after injection; however, in the kidney and heart, the highest expression was demonstrated after 7 days. The ribozyme expression was sustained for 7 or 14 days in the tissues, with decreasing levels, except for the liver. When two or three ribozyme injections, given at 5-day intervals, were administered to mice, the expression level improved in the synovium and heart ( Figure  2b ). As the highest expression of Rz666 was observed in synovium after three repeated injections, this treatment regimen was chosen for further in vivo studies.
Therapeutic activity of Rz666 on CIA
Given the successful transfection of the ribozyme in vivo, the inhibitory effect of Rz666 on CIA, a model largely dependent on TNF-a, [12] [13] [14] was then examined. Two independent experiments were performed, using groups of at least 10 mice, immunized with bovine type II collagen (BCII) in CFA. At 18 days after immunization, the mice were injected i.v. with the ribozyme-expressing vector three times, with 5-day intervals. Mice treated with mutant ribozyme following an otherwise identical protocol served as controls. The two experiments yielded similar results and pooled data of the experiments is shown in Figure 3 . Progressive arthritis developed in mutant-treated mice, and by day 40 after immunization, the disease incidence had reached 100% (Figure 3a) . At this time, the mice had severe clinical symptoms, with pronounced swelling and redness of the paws. In contrast, Rz666-treated mice were markedly resistant to the development of CIA, with only 40% of the mice exhibiting clinical signs of arthritis by day 40 (Po0.01). Further, the disease severity scores from day 40 and onward were significantly reduced in the Rz666-treated mice compared to mutant-treated mice (Po0.01) (Figure 3b ). 
Ribozyme targeting TNF-a inhibits autoimmune arthritis R Kumar et al
The joints from the mice were examined histologically to determine whether the amelioration of disease in mice transfected with Rz666 correlated with reduced joint pathology. Tissues of mice treated with mutant Rz666 displayed advanced stages of inflammation, including massive synovial hyperplasia, widespread infiltration of mononuclear cells and frequently, severe erosion of cartilage and bone (Figure 3c and d). Joints from arthritic Rz666-treated mice exhibited synovial hyperplasia and inflammatory cell infiltration, but almost no cartilage and bone erosion (Figure 3e ). Rz666-treated mice without clinical symptoms showed no pathological changes of the joints, synovial tissue was normal, and cartilage and underlying bone were intact ( Figure 3f ). Joint pathology examination (blind scoring) demonstrated that Rz666-treated animals had significantly reduced cartilage damage and bone erosion compared with mutant Rz666-treated mice (Figure 3g ). Infiltration of mononuclear cells into the joint cavity, however, was similar in both groups.
To investigate if Rz666 could suppress production of potentially arthritogenic anti-BCII antibodies, known to accompany the development of CIA when adoptively transferred to naïve mice, 10, 32, 33 serum samples collected at different times after BCII immunization of the mice were analyzed. No significant differences in serum IgG anti-BCII antibody levels were seen in Rz666-treated compared to mutant Rz666-treated mice (data not shown). We also analyzed serum samples for antiRz666 antibodies (to confirm that the pCI-neoRz666 construct did not elicit an immune response in the mice), but no antibodies to the ribozyme were detected (data not shown).
Rz666 effect on established arthritis
Having demonstrated that Rz666 treatment administered during the period of disease onset ameliorated CIA, the efficacy of the ribozyme on mice that had already developed clinical symptoms of arthritis was then tested. We treated the mice from the day of clinical disease onset with two i.v. injections of Rz666 or the mutant Rz666, at a 7-day interval. Rz666 strongly suppressed the progress of disease, an effect already apparent 1 day after the first Rz666 administration and lasting for more than 2 weeks (Figure 4 ). In the mutant-treated group, disease severity continued to increase.
The effect of the ribozyme on the local expression of TNF-a in joints of arthritic mice was also investigated. Mice were injected at the onset of CIA with a single dose of Rz666 or the mutant variant, and 24 h later, synovium and synovial fluid were collected from the knee joints. A trend of reduced mRNA and protein levels of TNF-a was noted in the Rz666-treated mice; however, the results did not significantly differ from that of mutant-treated mice (Figure 5a and b).
Discussion
Ribozymes represent a rapid and specific method for the selective inhibition of specific genes that are implicated in disease pathways. The central issue in ensuring the success of a ribozyme-based experiment is the proper selection of the target gene and the optimal design of the ribozyme. In our study, we designed a small hammerhead ribozyme consisting of 43 nt that could specifically cleave TNF-a mRNA. On increasing the molar ratio of the ribozyme to target, we observed an increase in the cleavage products in a ribozyme concentration-dependent manner.
One factor that can limit the accomplishment of gene therapy is the ability to target the gene to different tissues. We were though able to establish ribozyme expression in cells of various tissues of the mice, indicating the success of the systemic plasmid-based approach used here. Intravascular delivery of genes is attractive because the gene is disseminated throughout the tissue, as the vascular system has accesses to every cell. Previous studies in rodents have shown that tail vein delivery of naked DNA results in effective gene delivery to the liver (reviewed in Herweijer and Wolff 34 ). In our study, we made similar observation, in that the ribozyme was highly expressed in the liver. In addition, we observed that the ribozyme could be efficiently delivered to the spleen, kidney and heart, and also to the synovium. Even though the transfection of synovial cells was low, the ribozyme was present in healthy and in arthritic (data not shown) synovia after i.v. injection. This is novel and interesting, as expression of plasmid DNA in synovium has previously only been achieved via intra-articular injections. 35 TNF-a-specific ribozymes have been applied with varying success to inactivate TNF-a in vitro 28, [36] [37] [38] and to modulate LPS-induced TNF-a production by peritoneal cells in vivo. 39 However, the efficacy of ribozyme Ribozyme targeting TNF-a inhibits autoimmune arthritis R Kumar et al activity in the complex intracellular environment is difficult to predict and extrapolation of in vitro data to the in vivo situation, particularly under specific pathological conditions, is not always reliable. We investigated the action of our ribozyme in autoimmune arthritis. CIA was used as a model for RA and systemic administration of the ribozyme was shown to ameliorate the disease process. Ribozyme-mediated inhibition of TNF-a production not only dramatically reduced joint inflammation but also prevented structural damage such as cartilage and bone destruction. Inhibition of CIA was only mediated by the ribozyme containing a catalytically active core, as the inactive mutant ribozyme failed to inhibit the disease. The ribozyme had no influence on the serum levels of anti-collagen antibodies in the mice. This is consistent with former investigations in CIA using anti-TNF-a antibodies or soluble TNF receptors, indicating that inhibition of TNF-a does not interfere with the production of antibodies. [12] [13] [14] Further, the ribozyme treatment was also effective after the appearance of clinical symptoms. Disease progress was thus substantially retarded, seen as both a reduction in the number of initially affected limbs and lower numbers of additional limbs becoming affected, compared to mutant ribozyme-treated mice. The effectiveness of the TNF-atargeted ribozyme at established disease further provides insight into the important role of TNF-a in the development of clinical symptoms. Previous studies of CIA have demonstrated increased levels of TNF-a mRNA in lymphoid tissue at the time of disease manifestation. 40 Despite the successful suppression of CIA, inhibition of TNF-a locally in joints in the short term could not be fully verified. Similar findings has also been observed in RA patients, where anti-TNF-a antibodies have clinical benefits without suppressing TNF-a in the synovium. 41 It is likely that the overall reduction of TNF-a, as well as a reduction of TNFa-induced proinflammatory cytokines, may account for the clinical effects by the ribozyme, as we noted that circulating levels of TNF-a and IL-6 were diminished in CII-immunized Rz666-treated mice (data not shown). 
Ribozyme targeting TNF-a inhibits autoimmune arthritis R Kumar et al
At present, anti-TNF-a antibodies and soluble anti-TNF receptors are therapeutic in the treatment of RA, but with prominent side effects as a consequence of frequent injections of large doses of the proteins such as the risk of developing adverse immune reactions. Our results raise the possibility that a ribozyme strategy that inhibits TNFa and that is free from side effects could be superior to currently available anti-TNF agents; the low dose of the ribozyme used in our experiments (corresponding to 1.25 mg/kg body weight) was therapeutic and repeated doses of gene transfer with plasmid DNA induced no immune responses. Gene therapy also has one additional important advantage over protein therapies, as large quantities of highly purified plasmid DNA can be readily obtained at a relatively low cost.
The beneficial effect of the ribozyme lasted for at least 18 days after three injections and for 12 days after two injections. Long-lasting expression is particularly important in chronic diseases such as RA, which may require long-term therapy. It is conceivable that a higher dose of the ribozyme could increase expression and improve the efficacy of treatment, but alternatively, different delivery vehicles may also meet the intracellular expression levels necessary to extend the ribozyme therapeutic period and reduce the frequency of administration. Molecular delivery systems, such as liposomes or polymeric paste formulations, have been used to provide highly efficient transfection of oligonucleotides. 42, 43 In conclusion, the results presented here provide the first evidence that gene targeting by ribozymes modulates arthritis in vivo. We show that systemic delivery of plasmid-based ribozymes targeting TNF-a mRNA has a substantial therapeutic effect on arthritis and joint destruction in mice, proving that nonviral gene therapy vectors can be successfully used for in vivo treatments without inducing immune responses. The study also confirms the important role of TNF-a in the pathogenesis of autoimmune arthritis and emphasizes the potential clinical utility of a TNF-a targeting ribozyme strategy for the management of RA. This novel ribozyme approach could also be tested for its potential in other TNF-arelated inflammatory disorders such as psoriasis and Crohn's disease. Further innovation of ribozyme technology may open a new era in the treatment of autoimmune diseases.
Materials and methods
Design and cloning of ribozyme
Ribozyme-accessible target sites were analyzed for mTNF-a mRNA (GenBank accession no. M11731) by predicting the secondary structure using the programs MFOLD and FOLDRNA version 9.1 UNIX. 31 A ribozyme, denoted Rz666, was designed at nt position 666 in the coding region of mTNF-a mRNA (Figure 1a) . Rz666 (5 0 -AGGGGCTCTTCTGATGAGTCCGTGAGGACGAAA CGGCAGAGAGG-3') and its mutant variant, containing C instead of A at the marked position, were cloned immediately downstream of the T7 promoter at the StuI site of a pStuI phagemid (a modified pBKSII vector (Stratagene, La Jolla, CA, USA) incorporating a StuI site downstream of the T7 promoter). The ribozymes were also cloned into a pCI-neo mammalian expression vector (Promega, Madison, WI, USA) at an SmaI site. All constructs were confirmed by sequencing. The pCI-neo ribozyme constructs were amplified in DH5-a cells and purified using the endotoxin-free maxi kit (Qiagen, Valencia, CA, USA).
In vitro cleavage
pStuIRz666 was linearized with NotI and transcribed in vitro with T7 RNA polymerase (Riboprobe generation kit) according to the manufacturer's instructions Figure 4 Rz666 ameliorates established CIA. Mice were injected at days 1 and 8 after clinical onset of arthritis with pCI-neoRz666 m (n ¼ 10) or the pCI-neoRz666 mutant variant ' (n ¼ 9). The severity of arthritis is expressed as mean7s.e.m. P-value o0.0001 from days 2 to 9, P-value o0.01 from days 10 to 13 and P-value o0.05 on day 14. Ribozyme targeting TNF-a inhibits autoimmune arthritis R Kumar et al (Promega). Unincorporated nucleotides were removed by chromatography on a G-25 column and the yield was defined according to remaining radioactivity as estimated by Cherenkov counting. cDNA coding mTNF-a was generously provided by Dr Angelio Corti, Italy. The cDNA was subcloned in a pStuI vector at the EcoRV and BamHI sites. The plasmid was linearized with NotI and transcribed using T3 RNA polymerase and [a-
32 P]-labeled CTP. The mTNF-a RNA (2 pmol) and Rz666 (4 pmol) were mixed and heated at 801C for 2 min and immediately placed on ice for 3 min. Cleavage buffer (20 mM MgCl 2 , 50 mM Tris-HCl, pH 7.5) was added and the reaction was carried out at 371C for 1 h. Samples were run on 6% polyacrylamide gel containing 1 Â TBE buffer and 8 M urea. Analysis was carried out using a Fujix BAS 1800 PhosphorImager.
Expression of ribozyme in vivo
Single or repeated injections of 25 mg of pCI-neoRz666 in 200 ml of PBS were injected into the tail vein of DBA/1 mice. The mice were killed at different time points after injection and the synovium, liver, spleen, kidney and heart were dissected out. RNA was isolated from the tissues using the TriPure isolation reagent (Roche, Indianapolis, IN, USA) and real-time PCR was performed for comparative expression of the ribozyme.
Quantitative real-time PCR
Total RNA from the different tissues was quantified and reverse transcribed for generating cDNA using Advantaget RT-PCR kit (Clonetech) as per the manufacturer's instruction. Quantitative real-time PCR was performed using the SYBER Green PCR Master mix (PE Biosystems) and 300 nM of gene-specific forward and reverse primers: Rz666 as mentioned earlier, TNF-a as described previously, 44 and for b-actin forward primer, 5 0 -CATTATTG GCAACGAGCGG-3 0 , and reverse primer, 5 0 -TCCATACC CAAGAAGGAAGGC-3 0 . The reaction conditions were 10 min at 951C (one cycle), 15 s at 951C and 1 min at 601C (40 cycles). Gene-specific products were continuously measured by means of an ABI Prismt 7700 Sequence Detector (Applied Biosystem, Foster City, CA, USA). Samples were normalized using the housekeeping gene b-actin, and a comparative C T method was used for the analysis.
Induction and assessment of CIA
Age-and sex-matched DBA/1 mice (6-8 weeks old) were used. The DBA/1 mice were originally obtained from Bommice (Denmark) and were bred and maintained in the animal house of the Rudbeck Laboratory (Uppsala, Sweden) in a pathogen-free environment. To induce CIA, BCII, prepared as described, 45 was dissolved in 0.01 M acetic acid and emulsified in 1:1 CFA (Difco, Detroit, MI, USA). BCII (50 mg) was injected intradermally at the base of the tail. Arthritis development was assessed by clinical examinations 3 days per week, starting 21 days after immunization. Severity of arthritis was quantified according to a graded scale from 0 to 3 as follows: 0, normal; 1, detectable swelling in one joint; 2, swelling in more than one but not all the joints; and 3, severe swelling of the entire paw and/or ankylosis. Each limb was graded, with a possible maximum score of 12 per mouse.
All animal experiments were performed in compliance with the local ethics committee (Tierps tingsrätt) that approved the experiments.
Treatment schedule
Mice were treated with 25 mg (7 fmol) of pCI-neoRz666 in 200 ml of PBS, starting 18 days after BCII/CFA immunization. The ribozyme construct was injected i.v. into the tail vein three times, at intervals of 5 days. Mice that had developed arthritic symptoms were similarly treated, but received only two ribozyme injections and at an interval of 7 days. Control groups were similarly treated with a mutant ribozyme construct.
Measurement of serum antibodies
Serum samples were collected 20, 25, 30, 41 and 54 days after BCII immunization. The total level of IgG anti-BCII in sera of Rz666-or mutant Rz666-treated mice was measured using a BCII-specific ELISA as described. 46 Serum anti-Rz666 antibodies were analyzed 54 days after BCII immunization using a similar ELISA protocol, but with Rz666 as coating antigen.
Histological analysis
Eight randomly selected mice treated with three doses of either ribozyme or mutant ribozyme were killed 42 days after BCII/CFA immunization and forelimbs and hind paws were collected. The joints were fixed in 4% formaldehyde buffer, decalcified in Parengy decalcifying solution (chromium oxide, nitric acid and ethanol; The National Corporation of Swedish Pharmacies, Kungens Kurva, Sweden) and embedded in paraffin as described previously. 47 Sagital sections (5 mm) were stained with hematoxylin and eosin. Histopathological changes were recorded in a blinded score. The joint pathology was quantified according to a graded scale from 0 to 3 (normal to profuse changes) for each parameter: amount of cell infiltration, cartilage damage and bone erosion.
Expression of TNF-a in arthritic joints
Mice were injected i.v. at the onset of CIA with 25 mg of pCI-neoRz666 or the mutant variant in 200 ml of PBS. After 24 h, the mice were killed and synovium and synovial fluid were collected from the knee joints. RNA was isolated from the synovium and quantitative realtime PCR was performed for the expression level of TNFa mRNA. Protein level of TNF-a was measured in the synovial fluid samples with the mouse inflammation CBA kit (BDt Cytometric bead array, San Jose, CA, USA) according to the manufacturer's instructions.
Statistical analysis
The Mann-Whitney U-test was applied to the data from the arthritic score, w 2 was used for the analysis of arthritis incidence, and Student's t-test was used for cytokine and antibody levels.
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